Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Physiol ; 590(8): 1825-37, 2012 Apr 15.
Article in English | MEDLINE | ID: mdl-22331413

ABSTRACT

Virtually nothing is known about the effects on fetal physiology of xanthine oxidase inhibition. This is despite maternal treatment with the xanthine oxidase inhibitor allopurinol being considered in human complicated pregnancy to protect the infant's brain from excessive generation of ROS.We investigated the in vivo effects of maternal treatment with allopurinol on fetal cardiovascular function in ovine pregnancy in late gestation. Under anaesthesia, pregnant ewes and their singleton fetus were instrumented with vascular catheters and flow probes around an umbilical and a fetal femoral artery at 118±1 dGA (days of gestational age; termca. 145 days). Five days later, mothers were infused I.V. with either vehicle (n =11) or allopurinol (n =10). Fetal cardiovascular function was stimulated with increasing bolus doses of phenylephrine (PE) following maternal vehicle or allopurinol. The effects of maternal allopurinol on maternal and fetal cardiovascular function were also investigated following fetal NO blockade (n =6) or fetal ß1-adrenergic antagonism (n =7). Maternal allopurinol led to significant increases in fetal heart rate, umbilical blood flow and umbilical vascular conductance, effects abolished by fetal ß1-adrenergic antagonism but not by fetal NO blockade. Maternal allopurinol impaired fetal α1-adrenergic pressor and femoral vasopressor responses and enhanced the gain of the fetal cardiac baroreflex. These effects of maternal allopurinol were restored to control levels during fetal NO blockade. Maternal treatment with allopurinol induced maternal hypotension, tachycardia and acid­base disturbance. We conclude that maternal treatment with allopurinol alters in vivo maternal, umbilical and fetal vascular function via mechanisms involving NO and ß1-adrenergic stimulation. The evidence suggests that the use of allopurinol in clinical practice should be approached with caution.


Subject(s)
Cardiovascular System/embryology , Cardiovascular System/enzymology , Xanthine Oxidase/metabolism , Adrenergic beta-1 Receptor Antagonists/pharmacology , Allopurinol/pharmacology , Animals , Cardiovascular Physiological Phenomena/drug effects , Cardiovascular System/drug effects , Female , Fetus/drug effects , Fetus/enzymology , Gestational Age , Heart Rate, Fetal/drug effects , Nitric Oxide/antagonists & inhibitors , Pregnancy , Pregnancy Complications/drug therapy , Pregnancy Complications/metabolism , Regional Blood Flow/drug effects , Sheep , Uric Acid/blood , Xanthine Oxidase/antagonists & inhibitors
2.
FASEB J ; 25(1): 420-7, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20923964

ABSTRACT

Molecular mechanisms predisposing people to insulin resistance are starting to emerge. Altered insulin signaling for hepatic gluconeogenesis and muscle glucose uptake is thought to play a central role. Development under suboptimal conditions is also known to increase the risk of insulin resistance in adulthood. However, the partial contributions of reduced oxygen vs. nutrient delivery to the fetus, two common adverse conditions in utero, to developmental programming of insulin resistance remain unknown. The aim of this study was to determine the effects of developmental hypoxia or undernutrition on the expression of insulin-signaling proteins in liver and skeletal muscle in adult rat offspring. We show that the expression of hepatic phospho-Akt and muscle Akt2 were significantly reduced in offspring of hypoxic, relative to offspring from normoxic or undernourished, pregnancies. Hepatic Akt-1, Akt-2, and PKCζ protein expression was reduced in offspring from both hypoxic and undernourished pregnancies. Muscle GLUT4 expression was decreased in undernourished, and further decreased in hypoxic, offspring. These findings link prenatal hypoxia to down-regulation of components of hepatic and muscle Akt expression in adult offspring. Akt may represent a pharmaceutical target for clinical intervention against the developmental programming of metabolic disease resulting from prenatal hypoxia.


Subject(s)
Biomarkers/metabolism , Hypoxia/physiopathology , Insulin Resistance/physiology , Prenatal Exposure Delayed Effects , Animals , Blotting, Western , Body Weight , Female , Glucose Transporter Type 4/metabolism , Insulin/blood , Lipids/blood , Litter Size , Liver/metabolism , Male , Malnutrition/physiopathology , Muscle, Skeletal/metabolism , Pregnancy , Protein Kinase C/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Rats , Rats, Wistar , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...